• м.Ленинский проспект, ул.Фотиевой, д.10
  • м.Ясенево, Литовский бульвар, д.1А
О ЦКБ РАН

"Миколикопин" – новое лекарственное средство

"Миколикопин" – новое лекарственное средство для лечения рака простаты» (совместно с Институтом микробиологии им. С.Н. Виноградского РАН )

Полученные результаты являются оригинальными, так как впервые в мире для профилактики и лечения карциномы простаты используется ликопин, получаемый не из растений, а из мицелиальных грибов. Проект обладает не только новизной, но и имеет престижный характер для Российского производства в связи с впервые применяемыми биотехнологическими разработками. Полученный в лабораторных условиях Миколикопин, проверенный спектрофотометрическим методом на содержание активного начала (ликопина), был передан в Аккредитованный испытательный лабораторный центр ООО НБЦ «Фармбиомед» для проведения  испытаний. 

  We have developed a biotechnological method to produce a new stimulator of lycopene synthesis, MAP. This azine almost completely inhibits lycopene cyclization without producing any toxic effect. We have also obtained the fungal BAS Mycolycopene in the form of gelatin capsules that contain a 2% lycopene suspension and fungal BAS (ubiquinol, essential fatty acids, etc.) in sunflower oil. The tests conducted at the Laboratory for Developing Nontoxic Immunomodulators of the N.N. Blokhin Russian Oncology Center (Russian Academy of Medical Sciences) revealed that, apart from antioxidant activity, Mycolycopene possesses antimutagenic, radioprotective, and immunomodulating properties.

  We tested the antitumor effect of Mycolycopene on male rats of the ACI line with an inoculated prostate tumor obtained from inducible tumor tissues according to the procedure developed in the Laboratory for Experimental Tumor Endocrine Therapy of the N.N. Blokhin Russian Oncology Center (Russian Academy of Medical Sciences). For comparison, we used the peptide hormone surfagon, an analogue of luliberine (the gonadotropin superreleasing factor).

  The data indicate that an antitumor effect occurred in all groups except the control. The tumor growth deceleration (TGD) level with Mycolycopene (58%) after 20 days was close to that with surfagon (60%). The highest TGD values were obtained with the Mycolycopene–surfagon combination (68%). The combined effect of these preparations resulted in a better physical state of the rats involved (they had a smooth fur and were highly active) than the effect of surfagon alone. Accordingly, Mycolycopene is of indisputable interest in terms of prostate cancer therapy, based on its TGD value.

  We also tested the antitumor effect of Mycolycopene on male rats of the ACI line with an inoculated prostate tumor obtained from inducible tumor tissues according to the procedure developed in the Laboratory for Experimental Tumor Endocrine Therapy of the N.N. Blokhin Russian Oncology Center (Russian Academy of Medical Sciences). For comparison, we used the peptide hormone surfagon, an analogue of luliberine (the gonadotropin superreleasing factor). The rats were subdivided into four groups with ten rats in each. The test took 30 days, and the preparations were administered to them daily. The rats of the first group served as controls and received 0.2 ml of sunflower oil per diem. The rats of the second group were given Mycolycopene, starting from the second day after inoculating the tumor (2.5 mg/kg). The rats of the third group received 10 mg/kg of surfagon following tumor inoculation. The rats of the fourth group received surfagon and Mycolycopene, starting from the second day after inoculating the tumor.

  The data obtained are shown in the Figure. They indicate that an antitumor effect occurred in all groups except the control. The tumor growth deceleration (TGD) level with Mycolycopene (58%) after 20 days was close to that with surfagon (60%). The highest TGD values were obtained with the Mycolycopene–surfagon combination (68%). Importantly, the combined effect of these preparations resulted in a better physical state of the rats involved (they had a smooth fur and were highly active) than the effect of surfagon alone. Accordingly, Mycolycopene is of indisputable interest in terms of prostate cancer therapy, based on its TGD value.

Запись на прием
Запись на прием Online
Заявка отправлена

Наши специалисты свяжутся с вами, в ближайшее время

Запись на прием по телефону
(Основной)
+7 (499) 400-47-33
(Полисы ОМС, ДМС, льготы)
+7 (499) 137-83-52
  • Адрес
  • Адреса больниц:
  • м. Ясенево, Литовский бульвар, д 1 А
  • м. Ленинский проспект, ул. Фотиевой, д.10
  • Телефон
  • Время работы колл-центра:
  • Пн-Пт, с 08:00 до 20:00
  • Сб, с 09:00 до 17:00
(Вс - выходной)